UNSPSC 51171965: Benatoprazole or tenatoprazole

This classification denotes a proton pump inhibitor with the molecular formula C16H18N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RE0689TX2K, chemically known as 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1h-imidazo(4,5-b)pyridine but generally known as tenatoprazole, which bears US NIH Compound Identifier 636411. European Medicines Agency schedules Tenatoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04717MIG.

The term TENATOPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Benatoprazole or tenatoprazole bears US NLM identifiers UMLS ID C1455363 and NCI Concept Code C90934. SMILES: S(=O)(CC1NCC(C(OC)C1C)C)C1[NH]C2C(N1)NC(OC)CC2.

UNSPSC 51171965 Benatoprazole or tenatoprazole is a Commodity code that covers pharmaceutical active ingredients and finished medications. State and local procurement activity under this code does not show recent solicitations directly requesting benatoprazole or tenatoprazole by name. Instead, the recent opportunities tagged to this code are for broader pharmaceutical procurement — generic multi-source drugs and over-the-counter products through cooperative purchasing vehicles, offender drug testing services that may reference pharmaceutical screening protocols, and exploratory market research on direct-to-manufacturer pharmacy initiatives. The issuing bodies include state health agencies (Texas Health and Human Services Commission), county criminal justice departments (Collin County Community Supervision and Corrections), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering multi-state contracts). The actual procurement under this code appears to target state agencies and departments purchasing medications at scale through established wholesaler networks and cooperative agreements rather than individual branded or generic drug lines.

Recent activity spans Texas and Minnesota. The most concrete opportunity is the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802, posted January 20, 2026 with a March 26, 2026 deadline, which established multiple contracts for generic pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota, Oregon, and participating states. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (posted July 9, 2026, due July 23, 2026, estimated contract value $600,000), which involves pharmaceutical screening and testing methodologies. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope — a specific pharmaceutical compound — and the actual solicitations (generic drug pools, testing services, pharmacy program exploration) suggests limited targeted procurement activity under this exact commodity code in recent state and local notices.